The initial diagnosis and assessment of coronary artery disease (CAD) are important in risk stratification for future cardiovascular events and subsequent treatment choice. The current diagnostic approach to CAD is mainly based on anatomic and functional imaging. Stress myocardial perfusion imaging (MPI) or/and coronary CT angiography (CCTA) are commonly used for symptomatic chronic CAD patients. MPI is useful for detecting ischemia and assessing the severity of CAD.
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The initial diagnosis and assessment of coronary artery disease (CAD) are important in risk stratification for future cardiovascular events and subsequent treatment choice. The current diagnostic approach to CAD is mainly based on anatomic and functional imaging. Stress myocardial perfusion imaging (MPI) or/and coronary CT angiography (CCTA) are commonly used for symptomatic chronic CAD patients. MPI is useful for detecting ischemia and assessing the severity of CAD. 1 MPI is generally used for determining the appropriate approach to coronary intervention. In addition, semiquantitative analysis of myocardial ischemia by MPI provides highly useful information regarding the future outcomes. 2, 3 CCTA, on the other hand, is rapidly becoming a commonly used technique for diagnosing CAD with high accuracy. 4, 5 In particular, CT has been reported to have a high negative predictive value for suspected CAD and a high prognostic value. [6] [7] [8] Therefore, CCTA is being increasingly used as an alternative to MPI for the initial diagnosis of CAD, particularly in patients with low to intermediate probability of CAD.
In several recent studies, MPI and CCTA for risk analysis of stable CAD were compared. [9] [10] [11] The data obtained indicate comparative results in terms of longterm outcomes. However, a higher rate of revascularization is noted for patients who underwent CCTA than those who underwent MPI. These findings suggest that both noninvasive tests for detecting and excluding CAD are comparable in terms of diagnostic accuracy. MPI and CT provide information regarding different aspects of the disease-atherosclerotic and ischemic changes, respectively; thus, both tests complement each other. The higher rate of revascularization in CCTA may be explained by the tendency of cardiologists to consider coronary intervention when the CT performed initially shows significant coronary stenosis, whereas such an intervention may not be considered when the MPI performed initially does not show ischemia. Low-risk patients enrolled in our observational J-COMPASS Study in Japan also showed such a tendency. 11 The incidences of MACE including death, acute myocardial infarction, cardiac event, and late revascularization were 7.0%, 2.6%, and 2.1%/year when catheter, MPI, and CCTA were initially performed, respectively. The percentages of patients who underwent catheter after the initial tests by MPI and CCTA were 33% and 31%, respectively. The hazard ratio for early revascularization in CCTA compared with that in MPI was 1.62 (95% confidence interval: 1.20-2.08) and that for catheter was 5.36 (95% CI: 4.07-7.05).
In this issue of the Journal of Nuclear Cardiology, Cantoni et al. report on the first meta-analysis they conducted to compare the long-term prognostic values of MPI and CCTA for adverse cardiovascular events in patients with suspected or known CAD (XXX). Their meta-analysis confirmed similar long-term prognostic values of MPI and CCTA. In the MPI group, cardiac hard events occurred at 1.1%/year in patients with normal MPI findings and 2.9%/year in those with abnormal MPI findings [pooled hazard ratio, 2.32 (95% confidence interval, 1.95-2.75)]. In the CCTA group, cardiac hard events occurred at 0.7%/year in patients with nonsignificant stenosis and 4.6%/year in those with significant coronary stenosis of more than 50% [pooled hazard ratio, 4.35 (95% confidence interval, 2.66-7.13), P = NS compared with MPI]. On the other hand, the hazard ratio for the occurrence of a combination of endpoints including late revascularization was higher in the CCTA group than in the MPI group. In the MPI group, combined events occurred in 1.3%/year of patients with normal MPI findings and 5.2%/year of abnormal MPI findings [pooled hazard ratio, 2.71 (95% CI, 1.52-4.83)]. However, in the CCTA group, the event rate increased to 7.9%/year in patients with obstructive disease compared with 0.8%/year in those with nonobstructive disease [pooled hazard ratio, 7.61 (95% CI, 3.51-16.53], P \ 0.05 compared with MPI]. Although the authors did not provide possible reasons for these outcomes in their discussion, the main reason may have been explained by previous reports. Although the final outcome may not be significantly different between the two methods so far, we should carefully analyze, given the higher frequency of revascularization in the CCTA group, whether CCTA might be more or less beneficial for CAD patients. In this respect, long-term outcome studies may be required.
Although both the MPI and CCTA tests are effective for excluding CAD in patients with low and intermediate pretest probabilities in terms of long-term outcomes, MPI may be better for patients in whom contrast medium should be used with great caution and for those who are considered to have nondiagnostic findings such as high levels of coronary artery calcification prior to any CT examinations. Tests with lower radiation dosages could be another reason for selecting the imaging modality. Recently, 256-320 multislice CT with reconstruction using iterative approximation and D-SPECT realize low radiation dosages. On the other hand, the evaluation of the severity of CAD (i.e., more than 10% ischemia on MPI or twovessel disease on CCTA) is another issue in addition to the diagnosis of CAD in relation to the selection of appropriate treatments such as optimal medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). Indeed, in patients with multivessel CAD and diabetes mellitus, CABG is superior to PCI for improving prognosis. 12, 13 CCTA and MPI are complementary in assessing CAD burden once severe CAD is detected. For example, when more than 10% ischemia is observed by MPI, the location and number of stenotic sites assessed by CCTA or invasive catheter are the next concerns for cardiologists. Significant coronary stenosis in the proximal LAD or left main trunk may predict worse prognosis compared with the stenosis in branch arteries if the severity of ischemia is similar. On the other hand, when intermediate stenosis in the proximal LAD or left main trunk is observed by CCTA, the assessment of functional ischemia by stress MPI will be the next step. These different aspects of imaging tests suggest that in cases of moderate to severe, but not mild CAD, both the anatomic burden on CT and the ischemic burden on stress MPI could be often desirable. Recent CT examination enables us to simultaneously evaluate ischemia and coronary anatomy by stress perfusion CT and CTA. 14, 15 Moreover, fractional flow reserve estimation by CT (FFR_CT) for functional analysis is receiving much attention. FFR_CT increases the specificity for identifying positivity for invasive FFR compared with CCTA alone. 16, 17 Likewise, MRI provides stress MPI, scar imaging, and coronary angiography. 18, 19 Accordingly, cardiologists are interested in the simultaneous assessment of anatomical information and functional ischemia owing the latest technologies (Figure 1 ). PET/CT and SPECT/CT also provide information on myocardial ischemia and coronary artery calcium burden. Furthermore, PET/CT is the established method to assess quantitative myocardial blood flow and coronary flow reserve, which can greatly improve risk stratification of CAD. [20] [21] [22] From the above, both CTA and MPI as the initial tests are comparable in identifying and excluding the presence of CAD. However, in patients highly likely having or known to have CAD, information on both anatomic and ischemic burden could be useful for considering the strategy to improve prognosis. On the other hand, soft plaques with positive morphologic remodeling shown by CCTA 23 and MRI 24 are also considered for identifying patients at high risk CAD, but the appropriate use criteria of plaque assessment is as yet not established in the clinical settings.
Although MPI or CCTA alone, or both should be used appropriately considering the balance between diagnostic value, prognostic value, medical cost, and patients' burden, it would be valuable to realize complementary assessment of anatomy and functional ischemia by using the latest technologies in patients with CAD in the near future.
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